This trial is evaluating whether Lorlatinib will improve 1 primary outcome and 7 secondary outcomes in patients with Lung Cancer. Measurement will happen over the course of 12 weeks.
This trial requires 30 total participants across 1 different treatment group
This trial involves a single treatment. Lorlatinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The signs of carcinoma/NSCLC can be categorized as early or late. Early signs include hypercalcemia, bone pain (on palpation), and increased levels of liver-function enzymes. Late signs include weight loss and fatigue." - Anonymous Online Contributor
"The specific genetic events underlying carcinoma, non-small-cell lung have not been fully described; our present knowledge was based on the findings from large-scale analyses utilizing microarrays and the analysis of sporadic cases identified at large cancer registries. The present study highlights the importance of functional analyses of candidate tumor suppressor genes to elucidate the role of somatic mutations in carcinoma development." - Anonymous Online Contributor
"Non-small cell [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) is a disease of the lung, characterized by uncontrolled growth, metastasis and often death. It has been identified as one of the most lethal and common cancer in the world. Most often, lung cancer has metastasized at the time of diagnosis. To our knowledge, this article is the first to report the existence of a cancer vaccine for patients with lung cancer." - Anonymous Online Contributor
"Smoking cessation and weight control are often recommended treatment for lung cancer-associated non-smoking lifestyle-related factors. For patients with NSCLC that have been in remission by surgery or chemotherapy, the management depends on local and/or regional recurrence. Treatments include local radiation therapy and second line of chemotherapy.\n" - Anonymous Online Contributor
"Approximately 3.5 million US adult population receive [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) treatment. Approximately 4.5 million people die from lung cancer annually. Of these, more than half (2.7%) are younger than 35 years of age. More than half (4.3%) of the lung cancer death were smokers, which has already exceeded the 25% death reduction goal that the lung cancer goal set by the U.S. Preventive Services Task Force to reduce tobacco smoking and cancer." - Anonymous Online Contributor
"As with other cancers, the ability to cure carcinoma, non-small-cell lung is limited and not without some degree of doubt. However, it remains the most curable human malignancy." - Anonymous Online Contributor
"Lung carcinoma spreads quickly. Surgical resection alone is rarely definitive and may not be indicated in the presence of limited residual disease. In patients with small or limited tumors in situ, resection may suffice, especially in the absence of contraindications to surgery." - Anonymous Online Contributor
"The addition of lorlatinib to conventional chemotherapy was effective in patients with metastatic renal cell carcinoma, and results of this study support the use of lorlatinib for this indication." - Anonymous Online Contributor
"The most common clinical trials in this group were (1) [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) or solid tumor randomized Phase III trials with a mean of 3.6 months, and (2) cancer in children or adolescents with the most common mean duration of 1.7 months. All trials used the placebo arm in addition to the experimental arm, which was also the case for half of the trials. It is interesting to note that the placebo arm had a mean duration of 1.7 months. If the mean duration of clinical trials using lorlatinib in different clinical trials is so short, we need to evaluate whether the drug truly has an effect." - Anonymous Online Contributor
"More recent research has been focused on new therapeutic options rather than prevention of the disease, although much still remains to be investigated in order to better inform on risk/benefits and risk/benefits ratios. There is now more and more evidence in supporting the use of immunotherapy and more randomized controlled studies on new treatments." - Anonymous Online Contributor
"[The FDA Advisory Panel recommends that lorlatinib is not FDA approved for treatment of advanced NSCLC, but that lorlatinib should be considered in clinical trials for that indication.] The FDA Advisory Panel also indicates that lorlatinib should be evaluated in patients with advanced NSCLC whose disease has progressed. Patients with EGFR mutation may benefit from treatment with lorlatinib. [Drug Information from http://www.fda.gov/Drugs/Approved/New.htm]." - Anonymous Online Contributor
"Although no new information has been discovered in recent years for treating cancer, it is possible that we may not have had a chance to find a'magic bullet' that can eliminate cancer cells all together. It is hoped with such advances that more people will be able to live life to its fullest, while still not having too many side effects. It is crucial for oncologists and other physicians who treat patients to know when to stop treatment as more people live longer in different ways." - Anonymous Online Contributor